PRKN and cancer: The strategies have been adapted to target E1 enzymes, chaperones, histone deacetylases, proteasomal subunits and E3 ubiquitin ligases, like mouse double minute 2 homolog (MDM2), anaphase-promoting complex (APC), etc., to treat various types of cancers with varying success (Eldridge and O’brien, 2010; Shen et al., 2013; Weathington and Mallampalli, 2014).